This page shows the latest odanacatib news and features for those working in and with pharma, biotech and healthcare.
Merck &Co decided to drop its once-weekly cathepsin K inhibitor odanacatib last year.
Merck &Co has decided to discontinue development of its osteoporosis candidate odanacatib after seeing an elevated risk of stroke in studies. ... Meanwhile, the demise of odanacatib could also benefit Radius Health's new parathyroid hormone (PTH) based
odanacatib. However, a major shake-up in the osteoporosis market is expected to occur as generic competition to Lilly's big-selling PTH drug Forteo (teriparatide) starts to gather momentum.
The company had intended to file the drug for approval in 2013 but put that plan on hold while it looked into a'safety signal' of odanacatib. ... Treatment with odanacatib also led to progressive increases in bone mineral density (BMD) over five years at
alongside a major reworking of its R&D operations after a series of late-stage pipeline failures and delays including osteoporosis drug odanacatib, anaesthesia drug sugammadex and new insomnia candidate suvorexant.
odanacatib, and some investors have called for an acceleration in the company's R&D restructuring plans to reduce costs and boost productivity.
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...